BidaskClub lowered shares of Corcept Therapeutics (NASDAQ:CORT) from a hold rating to a sell rating in a research note released on Tuesday, BidAskClub reports.

Several other research firms have also recently weighed in on CORT. B. Riley cut Corcept Therapeutics from a buy rating to a neutral rating and cut their price target for the company from $22.00 to $12.00 in a report on Friday, February 1st. Zacks Investment Research cut Corcept Therapeutics from a hold rating to a sell rating in a report on Tuesday, February 5th. Cantor Fitzgerald cut Corcept Therapeutics from an overweight rating to a neutral rating and cut their price target for the company from $20.00 to $14.00 in a report on Friday, February 1st. Finally, ValuEngine lowered Corcept Therapeutics from a buy rating to a hold rating in a research note on Thursday, December 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a strong buy rating to the company’s stock. Corcept Therapeutics presently has an average rating of Hold and an average target price of $12.50.

NASDAQ CORT opened at $11.96 on Tuesday. The company has a market cap of $1.37 billion, a price-to-earnings ratio of 19.93 and a beta of 1.27. Corcept Therapeutics has a 1-year low of $9.14 and a 1-year high of $20.00.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Monday, February 25th. The biotechnology company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.04. The business had revenue of $66.80 million during the quarter, compared to analysts’ expectations of $70.43 million. Corcept Therapeutics had a return on equity of 30.30% and a net margin of 29.97%. The firm’s revenue for the quarter was up 25.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.77 EPS. As a group, equities research analysts expect that Corcept Therapeutics will post 0.83 earnings per share for the current fiscal year.

In related news, Director G Leonard Baker, Jr. acquired 100,000 shares of the stock in a transaction dated Tuesday, February 12th. The stock was acquired at an average cost of $11.39 per share, with a total value of $1,139,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.00% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the company. New York State Teachers Retirement System lifted its stake in shares of Corcept Therapeutics by 1.3% during the 4th quarter. New York State Teachers Retirement System now owns 65,094 shares of the biotechnology company’s stock worth $870,000 after acquiring an additional 867 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in shares of Corcept Therapeutics by 2.8% during the 4th quarter. State of Alaska Department of Revenue now owns 35,137 shares of the biotechnology company’s stock worth $469,000 after acquiring an additional 943 shares during the last quarter. NumerixS Investment Technologies Inc lifted its stake in shares of Corcept Therapeutics by 9.2% during the 4th quarter. NumerixS Investment Technologies Inc now owns 13,208 shares of the biotechnology company’s stock worth $172,000 after acquiring an additional 1,108 shares during the last quarter. Bank of Montreal Can lifted its stake in shares of Corcept Therapeutics by 33.1% during the 4th quarter. Bank of Montreal Can now owns 4,831 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 1,202 shares during the last quarter. Finally, Flinton Capital Management LLC lifted its stake in shares of Corcept Therapeutics by 8.7% during the 4th quarter. Flinton Capital Management LLC now owns 15,764 shares of the biotechnology company’s stock worth $211,000 after acquiring an additional 1,260 shares during the last quarter. 79.31% of the stock is owned by institutional investors and hedge funds.

About Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.

Further Reading: What is the LIBOR?

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.